Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × bemarituzumab × Gastrointestinal × Clear all

Phase

Phase 1 3 Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Genitourinary 1 Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 695 Fluorouracil 580 Capecitabine 504 Gemcitabine 426 Leucovorin 420 Irinotecan 402 Bevacizumab 397 Cisplatin 298 Radiotherapy 258 Cetuximab 224 S 1 (combination) 158 Paclitaxel 157 pembrolizumab 156 Docetaxel 144 Drug Therapy 127 Nivolumab 124 sintilimab 118 apatinib 118 tislelizumab 116 130-nm albumin-bound paclitaxel 111 durvalumab 109 Folfox protocol 105 Albumin-Bound Paclitaxel 99 Surgical Procedures, Operative 95 Panitumumab 95 camrelizumab 94 lenvatinib 93 Sorafenib 90 regorafenib 88 Radiation 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed

155 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡